title: Use of somatostatin analogues in obesity.
abstract: Obesity is a condition that results from dysregulation of energy balance. Insulin, a component of the efferent pathway of the energy-regulatory circuit, promotes storage of energy substrates in adipose tissue and is, therefore, a potential target for pharmacotherapy. Somatostatin and its analogues (octreotide and lanreotide) bind to somatostatin subtype 5 receptors on the beta-cell membrane, which limits insulin release and, consequently, may decrease adipogenesis. Somatostatin and its analogues have been used in trials in patients with paediatric hypothalamic obesity. These children have hypothalamic dysfunction, mainly due to brain tumours such as craniopharyngiomas, which are thought to generate increased vagal output, leading to hyperinsulinaemia and weight gain. Two small trials, each of 6 months' duration, in children with paediatric hypothalamic obesity showed either a minimal weight loss or stabilization of bodyweight. In children with Prader-Willi syndrome, the most common genetic hypothalamic disorder associated with hyperphagia, hyperghrelinaemia, massive obesity and other endocrine disturbances, somatostatin failed to control hyperphagia and weight gain in a small number of patients, although it lowered the levels of the anorexigenic hormone ghrelin. Long-acting release octreotide was recently used in hyperinsulinaemic obese adults without cranial pathology. Insulin suppression was associated with small decreases in the body mass indexes of obese subjects receiving the higher dosages of the drug, with an acceptable safety profile, similar to that in previous studies. In conclusion, somatostatin and its analogues, by suppressing beta-cell insulin secretion, can retard weight gain in children with hypothalamic obesity and induce a small amount of weight loss in some adults with hyperinsulinaemic obesity.
authors.affiliation: Department of Endocrinology, Diabetes and Metabolism, Panagia General Hospital, Thessaloniki, Greece. tzotzas@otenet.gr
authors.forename: Themistoklis
authors.initials: T
authors.lastname: Tzotzas
authors.forename: Kostas
authors.initials: K
authors.lastname: Papazisis
authors.forename: Petros
authors.initials: P
authors.lastname: Perros
authors.forename: Gerasimos E
authors.initials: GE
authors.lastname: Krassas
mesh_terms: D000328:Adult; D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D006727:Hormone Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007027:Hypothalamic Diseases / Q000150:complications; D009765:Obesity / Q000188:drug therapy*; D011218:Prader-Willi Syndrome; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D019440:Anti-Obesity Agents; D006727:Hormone Antagonists; D013004:Somatostatin
references.citation: Clin Endocrinol (Oxf). 2003 May;58(5):653-61
references.pmid: 12699450
references.citation: J Clin Endocrinol Metab. 1984 Mar;58(3):544-8
references.pmid: 6363441
references.citation: J Clin Endocrinol Metab. 2004 Nov;89(11):5435-40
references.pmid: 15531494
references.citation: Endocr Rev. 2006 Jun;27(4):371-97
references.pmid: 16543382
references.citation: Clin Ophthalmol. 2007 Sep;1(3):209-15
references.pmid: 19668474
references.citation: Diabetes. 1994 May;43(5):696-702
references.pmid: 8168647
references.citation: Curr Med Chem. 2004 Jun;11(12):1595-615
references.pmid: 15180566
references.citation: C R Biol. 2006 Aug;329(8):608-22; discussion 653-5
references.pmid: 16860279
references.citation: J Pediatr Endocrinol Metab. 2006 Feb;19(2):121-7
references.pmid: 16562584
references.citation: Horm Metab Res. 2006 Jul;38(7):442-6
references.pmid: 16933179
references.citation: J Clin Endocrinol Metab. 2004 Jul;89(7):3298-305
references.pmid: 15240606
references.citation: J Clin Endocrinol Metab. 1977 Jun;44(6):1038-53
references.pmid: 874043
references.citation: J Clin Endocrinol Metab. 2003 Jun;88(6):2586-92
references.pmid: 12788859
references.citation: J Neurosurg. 1998 Oct;89(4):547-51
references.pmid: 9761047
references.citation: Proc Soc Exp Biol Med. 1988 Dec;189(3):362-6
references.pmid: 2905062
references.citation: Intern Med. 1997 May;36(5):319-20
references.pmid: 9213165
references.citation: J Med Chem. 2003 Jun 5;46(12):2334-44
references.pmid: 12773038
references.citation: J Clin Endocrinol Metab. 2005 May;90(5):2681-90
references.pmid: 15687345
references.citation: Life Sci. 1979 Aug 13;25(7):561-6
references.pmid: 388132
references.citation: Clin Endocrinol (Oxf). 2003 Oct;59(4):492-9
references.pmid: 14510913
references.citation: Int J Obes Relat Metab Disord. 2004 Feb;28(2):330-3
references.pmid: 14708034
references.citation: Eur J Endocrinol. 1994 Jun;130(6):581-6
references.pmid: 8205258
references.citation: Drugs. 1997 Apr;53(4):681-99
references.pmid: 9098666
references.citation: Best Pract Res Clin Gastroenterol. 2002 Jun;16(3):493-509
references.pmid: 12079271
references.citation: Int J Obes (Lond). 2006 Feb;30(2):331-41
references.pmid: 16158082
references.citation: Curr Med Chem. 2001 Nov;8(13):1605-48
references.pmid: 11562281
references.citation: Obes Surg. 1993 May;3(2):197-200
references.pmid: 10757921
references.citation: Obes Res. 1995 Nov;3 Suppl 4:591S-603S
references.pmid: 8697062
references.citation: J Pediatr. 1999 Aug;135(2 Pt 1):162-8
references.pmid: 10431109
references.citation: Mol Endocrinol. 2003 Jan;17(1):93-106
references.pmid: 12511609
references.citation: Clin Endocrinol (Oxf). 2002 Oct;57(4):539-46
references.pmid: 12354137
references.citation: Horm Res. 1998;49(1):17-21
references.pmid: 9438780
references.citation: J Clin Endocrinol Metab. 2003 Aug;88(8):3573-6
references.pmid: 12915638
references.citation: Int J Obes (Lond). 2006 Feb;30(2):382-7
references.pmid: 16231029
references.citation: Recent Prog Horm Res. 1998;53:95-117; discussion 117-8
references.pmid: 9769705
references.citation: Arch Intern Med. 1991 Aug;151(8):1573-8
references.pmid: 1872661
references.citation: J Comp Physiol Psychol. 1981 Apr;95(2):278-87
references.pmid: 6112246
references.citation: Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Oct;13(3):409-18
references.pmid: 10909432
references.citation: J Clin Endocrinol Metab. 2007 Nov;92(11):4101-6
references.pmid: 17726084
references.citation: Metabolism. 1992 Sep;41(9 Suppl 2):76-9
references.pmid: 1518438
references.citation: Int J Obes (Lond). 2006 Feb;30(2):313-21
references.pmid: 16276365
references.citation: Science. 2005 Mar 25;307(5717):1909-14
references.pmid: 15790843
references.citation: J Clin Endocrinol Metab. 2005 Jul;90(7):3854-62
references.pmid: 15827099
references.citation: Science. 1973 Jan 5;179(4068):77-9
references.pmid: 4682131
references.citation: Acta Endocrinol Suppl (Copenh). 1987;286:19-25
references.pmid: 2892334
references.citation: Nutr Metab Cardiovasc Dis. 2008 Feb;18(2):158-68
references.pmid: 18061414
references.citation: Diabetes. 1997 Jun;46(6):1025-9
references.pmid: 9166675
references.citation: Obes Res. 2005 Sep;13(9):1572-9
references.pmid: 16222060
references.citation: Pharmacol Biochem Behav. 1982 Jun;16(6):897-902
references.pmid: 6125953
references.citation: Endocr Rev. 1995 Aug;16(4):427-42
references.pmid: 8521788
references.citation: Int J Obes Relat Metab Disord. 2003 Feb;27(2):219-26
references.pmid: 12587002
references.citation: Medicine (Baltimore). 1975 Jul;54(4):301-30
references.pmid: 1152672
references.citation: Neurosci Biobehav Rev. 1982 Summer;6(2):205-14
references.pmid: 7048155
references.citation: Int J Obes Relat Metab Disord. 2003 Aug;27(8):875-88
references.pmid: 12861227
references.citation: Nat Med. 2002 Jul;8(7):643-4
references.pmid: 12091883
references.citation: Int J Obes Relat Metab Disord. 1993 Sep;17(9):527-32
references.pmid: 8220655
references.citation: Obesity (Silver Spring). 2006 Jun;14(6):1028-37
references.pmid: 16861608
references.citation: N Engl J Med. 1996 Jan 25;334(4):246-54
references.pmid: 8532003
references.citation: Clin Chim Acta. 2007 Jan;375(1-2):20-35
references.pmid: 16956601
references.citation: J Biol Chem. 1991 Jan 15;266(2):837-43
references.pmid: 1702440
references.citation: J Pediatr. 2005 Apr;146(4):474-81
references.pmid: 15812449
references.citation: J Clin Endocrinol Metab. 2004 Aug;89(8):4162-5
references.pmid: 15292365
references.citation: Expert Opin Investig Drugs. 2006 Aug;15(8):897-915
references.pmid: 16859393
references.citation: J Clin Endocrinol Metab. 2006 May;91(5):1811-8
references.pmid: 16507637
references.citation: Obes Rev. 2002 Feb;3(1):27-34
references.pmid: 12119657
references.citation: Front Neuroendocrinol. 2003 Jan;24(1):1-10
references.pmid: 12609497
references.citation: Trends Genet. 1998 May;14(5):194-200
references.pmid: 9613204
references.citation: Lancet. 1983 Jun 11;1(8337):1330-1
references.pmid: 6134114
references.citation: Nutr Rev. 1998 Apr;56(4 Pt 1):106-14
references.pmid: 9584495
references.citation: Gut. 2003 Nov;52(11):1555-61
references.pmid: 14570722
references.citation: Endocrinology. 2000 Jan;141(1):111-7
references.pmid: 10614629
references.citation: J Clin Endocrinol Metab. 2003 May;88(5):2180-4
references.pmid: 12727973
references.citation: Diabetologia. 1985 Feb;28(2):70-5
references.pmid: 3884419
references.citation: Prog Brain Res. 2006;153:57-73
references.pmid: 16876568
references.citation: Eur J Endocrinol. 2005 Jun;152(6):887-94
references.pmid: 15941929
references.citation: Fertil Steril. 2006 Jul;86 Suppl 1:S28-9
references.pmid: 16798283
references.citation: Pediatr Endocrinol Rev. 2004 Aug;1 Suppl 3:448-54
references.pmid: 16444173
references.citation: J Pediatr. 2006 Jan;148(1):23-9
references.pmid: 16423593
references.citation: J Clin Endocrinol Metab. 2001 Sep;86(9):4330-8
references.pmid: 11549670
references.citation: J Endocrinol Invest. 1997 Jun;20(6):348-67
references.pmid: 9294784